Download full-text PDF

Source
http://dx.doi.org/10.1097/00000637-200107000-00025DOI Listing

Publication Analysis

Top Keywords

rarely cutaneous
4
cutaneous lesions
4
lesions elderly
4
elderly patient
4
patient malignant
4
malignant transformation
4
transformation multiple
4
multiple trichoepithelioma
4
rarely
1
lesions
1

Similar Publications

Cutaneous absorption of methylene chloride is rarely toxic. This case shows that it can lead to carboxyhemoglobinemia. Exposure to methylene chloride should warrant a carboxyhemoglobin check and oxygen support.

View Article and Find Full Text PDF

Tumor necrosis factor-alpha (TNF-α) inhibitors are commonly used for management of various autoimmune disorders but can rarely cause isolated cutaneous lupus. This report presents two cases of cutaneous lupus erythematosus (LE) in women aged 38 and 61 after adalimumab treatment for psoriasis highlighting the importance of recognizing these paradoxical reactions for timely management.

View Article and Find Full Text PDF

Phototoxic reaction to oral terbinafine due to Tinea capitis in a child.

Acta Dermatovenerol Croat

November 2024

Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;

We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).

View Article and Find Full Text PDF

spp. rarely cause infection in humans and are most common in the immunocompromised population. Pulmonary nocardiosis is the most common presentation.

View Article and Find Full Text PDF

Introduction: Bortezomib is a reversible proteasome inhibitor that is a first-line chemotherapeutic agent for multiple myeloma. Bortezomib can be administered intravenously or subcutaneously with similar efficacy. Subcutaneous administration has fewer side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!